ADMA Biologics, Inc.

ADMA

US0008991046

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
12.78 ^USD	+3.82%		+11.52%	+182.74%

Jul. 09	Cantor Fitzgerald Adjusts Price Target on ADMA Biologics to $15 From $10, Maintains Overweight Rating	MT
Jul. 01	ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 3000E Value Index	CI

ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 3000E Growth Index

July 30, 2024

Latest news about ADMA Biologics, Inc.

Cantor Fitzgerald Adjusts Price Target on ADMA Biologics to $15 From $10, Maintains Overweight Rating	Jul. 09	MT
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 3000E Value Index	Jun. 30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 3000E Index	Jun. 30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell Microcap Index	Jun. 30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 3000 Value Index	Jun. 30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 2500 Value Index	Jun. 30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell Microcap Growth Index	Jun. 30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 3000E Growth Index	Jun. 30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 2000 Value Index	Jun. 30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell Microcap Value Index	Jun. 30	CI
Mizuho Securities Raises Price Target on ADMA Biologics to $14 From $12, Maintains Buy Rating	Jun. 20	MT
Adma Biologics Insider Sold Shares Worth $2,548,580, According to a Recent SEC Filing	Jun. 17	MT
HC Wainwright Adjusts ADMA Biologics' Price Target to $10 From $7.50, Maintains Buy Rating	May. 10	MT
Cantor Fitzgerald Adjusts ADMA Biologics' Price Target to $10 From $8, Maintains Overweight Rating	May. 10	MT
ADMA Biologics Shares Rise After Company Swings to Q1 Earnings, Lifts 2024 Guidance	May. 10	MT
ADMA Biologics Swings to Q1 Earnings, Revenue Rises; Lifts 2024 Guidance	May. 10	MT
ADMA Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q1 Revenue $81.9M, vs. Street Est of $77.3M	May. 09	MT
ADMA Biologics, Inc. Revises Earnings Guidance for the Full Year 2024 and 2025	May. 09	CI
Transcript : ADMA Biologics, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer	Apr. 02	CI
HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating	Mar. 26	MT
Adma Biologics Insider Sold Shares Worth $2,803,741, According to a Recent SEC Filing	Mar. 20	MT
Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam	Mar. 11	CI

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ADMA Biologics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.78 USD

Average target price

12.25 USD

Spread / Average Target

-4.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ADMA BIOLOGICS, INC.	+182.74%	2.96B
CSL LIMITED	+6.96%	101B
SAMSUNG BIOLOGICS CO.,LTD.	+8.29%	42.63B
BIOGEN INC.	-11.09%	33.5B
UCB	+82.32%	29.77B
BIOMARIN PHARMACEUTICAL INC.	-11.82%	16.14B
INCYTE CORPORATION	+1.39%	14.31B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.13%	11.55B
ALTEOGEN INC.	+176.65%	10.53B
SWEDISH ORPHAN BIOVITRUM AB	+6.74%	9.2B

Biopharmaceuticals